Skip to main content
. Author manuscript; available in PMC: 2024 Aug 16.
Published in final edited form as: Clin Cancer Res. 2024 Feb 16;30(4):803–813. doi: 10.1158/1078-0432.CCR-23-2274

Table 2:

Association between PD-1 Treg/CD8 ratio (measured as continuous variable) and clinical outcomes.

Treatment Arm PFS HR (90% CI; p-value) OS HR (90% CI; p-value) ORR OR (90% CI; p-value)
Everolimus 0.93 (0.82–1.05; 0.838) 0.91 (0.79–1.05; 0.860) NA
Nivolumab 1.24 (1.04–1.47; 0.023) 1.22 (1.04–1.449; 0.022) 0.57 (0.31–1.03; 0.060)